S&P 500   5,115.70 (-1.60%)
DOW   37,923.96 (-1.39%)
QQQ   437.99 (-1.66%)
AAPL   174.93 (-0.06%)
MSFT   420.95 (-1.63%)
META   512.37 (-2.06%)
GOOGL   157.53 (-1.18%)
AMZN   185.59 (-1.83%)
TSLA   171.09 (-2.01%)
NVDA   886.80 (-2.14%)
AMD   162.90 (-4.46%)
NIO   4.11 (-7.85%)
BABA   71.95 (-3.87%)
T   16.33 (-0.55%)
F   12.60 (-3.37%)
MU   122.59 (-3.86%)
GE   154.08 (-2.11%)
CGC   7.96 (-2.33%)
DIS   114.27 (-2.46%)
AMC   2.67 (-4.64%)
PFE   25.88 (-1.75%)
PYPL   64.65 (-1.75%)
XOM   121.40 (-0.32%)
S&P 500   5,115.70 (-1.60%)
DOW   37,923.96 (-1.39%)
QQQ   437.99 (-1.66%)
AAPL   174.93 (-0.06%)
MSFT   420.95 (-1.63%)
META   512.37 (-2.06%)
GOOGL   157.53 (-1.18%)
AMZN   185.59 (-1.83%)
TSLA   171.09 (-2.01%)
NVDA   886.80 (-2.14%)
AMD   162.90 (-4.46%)
NIO   4.11 (-7.85%)
BABA   71.95 (-3.87%)
T   16.33 (-0.55%)
F   12.60 (-3.37%)
MU   122.59 (-3.86%)
GE   154.08 (-2.11%)
CGC   7.96 (-2.33%)
DIS   114.27 (-2.46%)
AMC   2.67 (-4.64%)
PFE   25.88 (-1.75%)
PYPL   64.65 (-1.75%)
XOM   121.40 (-0.32%)
S&P 500   5,115.70 (-1.60%)
DOW   37,923.96 (-1.39%)
QQQ   437.99 (-1.66%)
AAPL   174.93 (-0.06%)
MSFT   420.95 (-1.63%)
META   512.37 (-2.06%)
GOOGL   157.53 (-1.18%)
AMZN   185.59 (-1.83%)
TSLA   171.09 (-2.01%)
NVDA   886.80 (-2.14%)
AMD   162.90 (-4.46%)
NIO   4.11 (-7.85%)
BABA   71.95 (-3.87%)
T   16.33 (-0.55%)
F   12.60 (-3.37%)
MU   122.59 (-3.86%)
GE   154.08 (-2.11%)
CGC   7.96 (-2.33%)
DIS   114.27 (-2.46%)
AMC   2.67 (-4.64%)
PFE   25.88 (-1.75%)
PYPL   64.65 (-1.75%)
XOM   121.40 (-0.32%)
S&P 500   5,115.70 (-1.60%)
DOW   37,923.96 (-1.39%)
QQQ   437.99 (-1.66%)
AAPL   174.93 (-0.06%)
MSFT   420.95 (-1.63%)
META   512.37 (-2.06%)
GOOGL   157.53 (-1.18%)
AMZN   185.59 (-1.83%)
TSLA   171.09 (-2.01%)
NVDA   886.80 (-2.14%)
AMD   162.90 (-4.46%)
NIO   4.11 (-7.85%)
BABA   71.95 (-3.87%)
T   16.33 (-0.55%)
F   12.60 (-3.37%)
MU   122.59 (-3.86%)
GE   154.08 (-2.11%)
CGC   7.96 (-2.33%)
DIS   114.27 (-2.46%)
AMC   2.67 (-4.64%)
PFE   25.88 (-1.75%)
PYPL   64.65 (-1.75%)
XOM   121.40 (-0.32%)
NASDAQ:ALGS

Aligos Therapeutics (ALGS) Stock Price, News & Analysis

$1.04
-0.02 (-1.42%)
(As of 01:00 PM ET)
Today's Range
$1.04
$1.08
50-Day Range
$0.64
$1.13
52-Week Range
$0.54
$1.38
Volume
192,464 shs
Average Volume
363,919 shs
Market Capitalization
$79.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Aligos Therapeutics MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.15% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.80
Upright™ Environmental Score
News Sentiment
0.86mentions of Aligos Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.83) to ($0.82) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.45 out of 5 stars

Medical Sector

1693rd out of 2,784 stocks

Biological Products, Except Diagnostic Industry

289th out of 465 stocks

ALGS stock logo

About Aligos Therapeutics Stock (NASDAQ:ALGS)

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

ALGS Stock Price History

ALGS Stock News Headlines

The next Nvidia (and it’s not Microsoft or Facebook)
Imagine buying Bitcoin at $1,000. That would have been the trade of the decade... right? Well, I think there's an even bigger play to be made in the A.I. space.
Aligos Therapeutics (NASDAQ:ALGS) Stock Price Up 2.9%
Aligos Therapeutics Inc (ALGS)
The next Nvidia (and it’s not Microsoft or Facebook)
Imagine buying Bitcoin at $1,000. That would have been the trade of the decade... right? Well, I think there's an even bigger play to be made in the A.I. space.
Recap: Aligos Therapeutics Q4 Earnings
Tracking Baker Brothers Portfolio - Q4 2023 Update
Aligos Therapeutics, Inc. (ALGS)
See More Headlines
Receive ALGS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aligos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/12/2024
Today
4/12/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ALGS
Fax
N/A
Employees
66
Year Founded
N/A

Profitability

Net Income
$-87,680,000.00
Net Margins
-607.03%
Pretax Margin
-559.49%

Debt

Sales & Book Value

Annual Sales
$15.53 million
Book Value
$1.23 per share

Miscellaneous

Free Float
63,184,000
Market Cap
$80.21 million
Optionable
Optionable
Beta
2.34
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Lawrence M. Blatt MBA (Age 62)
    Ph.D., CEO, President & Chairman of the Board
    Comp: $832.73k
  • Dr. Julian A. Symons DPHIL (Age 62)
    Executive VP & Chief Scientific Officer
    Comp: $618.66k
  • Ms. Lesley Ann Calhoun CPA (Age 58)
    Executive VP & CFO
  • Kristina Engeseth
    VP and Head of People & Culture
  • Dr. Matthew W. McClure M.D. (Age 52)
    Executive VP & Chief Medical Officer
  • Dr. Sushmita M. Chanda DABT (Age 57)
    Ph.D., Executive Vice President of Translational Safety Sciences
  • Dr. David B. Smith Ph.D.
    Executive VP & Head of Chemical Operations
  • Dr. Tse-I Lin Ph.D.
    VP of Early Compound Development & Belgian Site Head

ALGS Stock Analysis - Frequently Asked Questions

How have ALGS shares performed in 2024?

Aligos Therapeutics' stock was trading at $0.6640 at the start of the year. Since then, ALGS stock has increased by 56.6% and is now trading at $1.04.
View the best growth stocks for 2024 here
.

Are investors shorting Aligos Therapeutics?

Aligos Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 868,800 shares, an increase of 137.6% from the March 15th total of 365,600 shares. Based on an average daily trading volume, of 376,700 shares, the short-interest ratio is presently 2.3 days.
View Aligos Therapeutics' Short Interest
.

When is Aligos Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ALGS earnings forecast
.

How were Aligos Therapeutics' earnings last quarter?

Aligos Therapeutics, Inc. (NASDAQ:ALGS) issued its quarterly earnings data on Tuesday, March, 12th. The company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.05. The business earned $2.68 million during the quarter, compared to the consensus estimate of $3.20 million. Aligos Therapeutics had a negative net margin of 607.03% and a negative trailing twelve-month return on equity of 116.41%.

When did Aligos Therapeutics IPO?

Aligos Therapeutics (ALGS) raised $150 million in an initial public offering on Friday, October 16th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P.Morgan, Jefferies and Piper Sandler served as the underwriters for the IPO and Cantor was co-manager.

How do I buy shares of Aligos Therapeutics?

Shares of ALGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALGS) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners